News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA)'s Copaxone Conversion Effort Persuading Analysts Of Target


3/12/2014 8:02:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries Ltd.’s (TEVA:US) early progress in shifting daily Copaxone takers to a new formulation has persuaded some analysts the drugmaker may succeed in converting as many as half of its multiple sclerosis patients. Teva converted 8.7 percent of total 20-milligram Copaxone prescriptions to its 40-milligram injections for the week ending Feb. 28, according to Bloomberg Industries. Leerink Swann & Co. and Cowen & Co. analysts said the results mean the world’s largest maker of generic drugs may deliver on its plan to bring round 30 percent to 50 percent of patients to the three-times-weekly version.

Help employers find you! Check out all the jobs and post your resume

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES